Positioned to transform the HBV treatment landscape and address the HBV global market opportunity



Learn How >



Portfolio of assets combining multiple technologies aimed at curing HBV



Learn How >



Proven scientific leadership in antiviral and RNAi drug discovery and development



Learn How >

About Arbutus Biopharma

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

 

In addition to our HBV Assets, we have developed a proprietary delivery platform Lipid Nanoparticle (LNP), which is a proven delivery technology in RNA interference (RNAi) development.

 

Read More

 

 

R&D Portfolio

Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include our lead RNAi asset ARB-1467, our capsid assembly inhibitor AB-423 and multiple pre-clinical assets.

 

View Our R&D Portfolio